U.S. markets close in 2 hours 50 minutes
  • S&P 500

    3,804.04
    -14.79 (-0.39%)
     
  • Dow 30

    30,867.01
    -162.30 (-0.52%)
     
  • Nasdaq

    11,102.75
    -75.14 (-0.67%)
     
  • Russell 2000

    1,718.40
    -0.97 (-0.06%)
     
  • Crude Oil

    107.15
    -2.63 (-2.40%)
     
  • Gold

    1,810.90
    -6.60 (-0.36%)
     
  • Silver

    20.36
    -0.37 (-1.80%)
     
  • EUR/USD

    1.0485
    +0.0042 (+0.40%)
     
  • 10-Yr Bond

    2.9830
    -0.1100 (-3.56%)
     
  • GBP/USD

    1.2169
    +0.0047 (+0.39%)
     
  • USD/JPY

    135.6280
    -0.9170 (-0.67%)
     
  • BTC-USD

    19,105.57
    -907.16 (-4.53%)
     
  • CMC Crypto 200

    410.60
    -20.87 (-4.84%)
     
  • FTSE 100

    7,169.28
    -143.04 (-1.96%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

BeiGene's Brukinsa Applications Under FDA, European Review For Leukemia

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).

  • In November 2021, Brukinsa received its first approval in the European Union (EU) for Waldenström's macroglobulinemia (WM), who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy.

  • Additionally, the FDA has also accepted for review BeiGene's supplemental marketing application for Brukinsa for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL is the most common form of adult leukemia.

  • The Prescription Drug User Fee Act (PDUFA) target action date is October 22.

  • Price Action: BGNE shares are down 2.82% at $207.00 during the market session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.